Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2009-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-09-0366PMID 19671735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

  2009influential reference
• Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.

  2009cited by this paper
• Ixabepilone, a novel epothilone analog in the treatment of breast cancer.

  2008cited by this paper
• Discovery and Development of the Epothilones

  2008cited by this paper
• Vinflunine: A New Microtubule Inhibitor Agent

  2008cited by this paper
• Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

  2008cited by this paper
• Ixabepilone for the treatment of solid tumors: a review of clinical data.

  2008cited by this paper
• The Epothilones: Translating from the Laboratory to the Clinic

  2008cited by this paper
• Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.

  2008influential reference
• Preclinical discovery of ixabepilone, a highly active antineoplastic agent

  2008cited by this paper
• Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study

  2007influential reference
• Markers predicting clinical benefit in breast cancer from microtubule-targeting agents.

  2007cited by this paper
• Phase II study of vinflunine in malignant pleural mesothelioma.

  2007cited by this paper
• Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

  2007cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins

  2007cited by this paper
• Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen

  2007influential reference
• Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)

  2007cited by this paper
• Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues.

  2007cited by this paper
• Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer

  2007cited by this paper
• Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and/or metastatic disease stratified by prior chemotherapy

  2007cited by this paper
• Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)

  2007cited by this paper
• Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment.

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

  2007cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

  2007cited by this paper
• Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

  2007cited by this paper
• Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

  2007cited by this paper
• Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.

  2007influential reference
• Alterations in γ-Actin and Tubulin-Targeted Drug Resistance in Childhood Leukemia

  2006influential reference
• Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.

  2006cited by this paper
• A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

  2006cited by this paper
• First-in-human phase I trial of a novel epothilone, KOS-1584.

  2006cited by this paper
• A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen.

  2006cited by this paper
• The Chemistry and Biology of Epothilones—Lead Structures for the Discovery of Improved Microtubule Inhibitors

  2006cited by this paper
• Predictive factors for response to docetaxel in human breast cancers

  2006cited by this paper
• Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on Tubulin

  2006cited by this paper
• The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

  2005influential reference
• Targeting microtubules for cancer chemotherapy.

  2005cited by this paper
• Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

  2005cited by this paper
• Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

  2005cited by this paper
• Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

  2005cited by this paper
• βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability*

  2005cited by this paper
• Labelling of cells with quantum dots

  2005cited by this paper
• Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.

  2005cited by this paper
• Vinflunine: a novel antitubulin agent in solid malignancies

  2005cited by this paper
• Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

  2005cited by this paper
• Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells

  2005cited by this paper
• Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy

  2005cited by this paper
• Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses

  2005cited by this paper
• Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer

  2005cited by this paper
• Regulation of Bax Activation and Apoptotic Response to Microtubule-damaging Agents by p53 Transcription-dependent and -independent Pathways*

  2004influential reference
• Microtubules as a target for anticancer drugs

  2004influential reference
• Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389

  2004cited by this paper
• BMS-310705 Bristol-Myers Squibb/GBF.

  2004cited by this paper
• The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography

  2004influential reference
• Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

  2004cited by this paper
• Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells.

  2003cited by this paper
• DJ‐927, a novel oral taxane, overcomes P‐glycoprotein‐mediated multidrug resistance in vitro and in vivo

  2003influential reference
• Medicinal Chemistry Of Bioactive Natural Products

  2003cited by this paper
• Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.

  2003cited by this paper
• Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.

  2002cited by this paper
• Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

  2002cited by this paper
• Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.

  2002cited by this paper
• Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules.

  2002cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view.

  2001cited by this paper
• Cancer Chemotherapy and Biotherapy: Principles and Practice

  2001cited by this paper
• Structural insight into microtubule function.

  2001influential reference
• Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.

  2001cited by this paper
• BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

  2001cited by this paper
• Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity.

  2000influential reference
• The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis.

  2000cited by this paper
• DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.

  1999cited by this paper
• Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.

  1998cited by this paper
• The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells

  1998cited by this paper
• Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization*

  1997cited by this paper
• Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes.

  1997cited by this paper
• Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.

  1996cited by this paper
• Structure of tubulin at 6.5 Å and location of the taxol-binding site

  1995cited by this paper
• Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

  1995cited by this paper
• In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins.

  1994cited by this paper
• [Antimicrotubule agents].

  1993cited by this paper
• Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

  1971cited by this paper

• Marine natural product-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivative CHNQD-01522: A novel anti-hepatocellular carcinoma agent targeting colchicine binding site of microtubule.

  2026cites this paper
• Bispecific antibody–drug conjugates: a modular blueprint for next-generation cancer therapeutics

  2026cites this paper
• Discovery of Peptide-Based Tubulin Inhibitors Through Structure-Guided Design.

  2026cites this paper
• An N-linked imidazo[1,2-a]pyridine benzoheterobicyclic hybrid inhibits mitosis and cancer cell proliferation by targeting tubulin.

  2025cites this paper
• Tubulin targeting agents and their implications in non-cancer disease management.

  2025cites this paper
• Acupoint Catgut Embedding at Stellate Ganglion Combined with Oral Mecobalamin Versus Mecobalamin Monotherapy in Managing Taxane-Induced Peripheral Neurotoxicity: A Clinical Observational Study

  2025cites this paper
• Connectivity mapping with isotretinoin's transcriptomic signature identifies alternative therapeutics for severe acne.

  2025cites this paper
• Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer

  2025cites this paper
• Design and development of new substituted pyrimidine hybrids with imidazole and triazole: Exploring utility as an anticancer agent via human topoisomerase-II and tubulin inhibition.

  2025cites this paper
• Convection-Enhanced Delivery of Auristatin-Conjugated Layer-by-Layer Nanoparticles for Glioblastoma Treatment.

  2025cites this paper
• Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells

  2025cites this paper
• Taxane-Induced Conformational Changes in the Microtubule Lattice Activate GEF-H1-Dependent RhoA Signaling

  2025cites this paper
• Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells

  2025cites this paper
• Cellular Senescence in Cancer: Mechanisms, Roles in Tumor Progression, and Therapeutic Implications

  2025cites this paper
• Design, synthesis and anticancer evaluation of novel 1,3-imidazole-type phenylhistin derivatives: Dual mechanism via P53 induction and microtubulin inhibition.

  2025cites this paper
• Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy.

  2025cites this paper
• Discovery of a novel potent tubulin inhibitor through virtual screening and target validation for cancer chemotherapy

  2025cites this paper
• Synthesis, characterization, docking, MD simulation, and evaluation of antiproliferative effectiveness of new 4-aminobenzophenone derivatives

  2025cites this paper
• Thiazolotriazoles: Their Biological Activity and Structure-Activity Relationships.

  2025cites this paper
• Discovery of Novel 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(2H)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer Activity.

  2025cites this paper
• PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy.

  2025cites this paper
• Structure based drug design and machine learning approaches for identifying natural inhibitors against the human αβIII tubulin isotype

  2025cites this paper
• Anticancer Potential of Halogen Derivatives of Methyl 6-Acetyl-5-Hydroxy-2-Methyl-1-Benzofuran-3-Carboxylate

  2025cites this paper
• Bovine tubulin cofactor D (TBCD) disrupts tubulin dimers and inhibits tumor growth via the TNF-α signaling pathways-mediated ROS production.

  2025cites this paper
• Phosphoinositide signaling at the cytoskeleton in the regulation of cell dynamics

  2025cites this paper
• PayloadGenX, a multi-stage hybrid virtual screening approach for payload design: A microtubule inhibitor case study

  2025cites this paper
• BM7, a derivative of benzofuran, effectively fights cancer by promoting cancer cell apoptosis and impacting IL-6 levels.

  2024cites this paper
• Downregulation of mesenteric afferent sensitivity following long-term systemic treatment of vincristine in mice.

  2024cites this paper
• First total synthesis, antitumor evaluation and target identification of mornaphthoate E: A new tubulin inhibitor template acting on PI3K/Akt signaling pathway

  2024cites this paper
• Mechanisms of mitotic inhibition in human aorta endothelial cells: Molecular and morphological in vitro spectroscopic studies.

  2024cites this paper
• Benzothiazole‐based apoptosis inducers: A comprehensive overview and future prospective

  2024cites this paper
• Design and bio-evaluation of novel millepachine derivatives targeting tubulin colchicine binding site for treatment of osteosarcoma.

  2024cites this paper
• Exploring the cancer-fighting properties of Catharanthus roseus: A natural powerhouse

  2024cites this paper
• The Role of ZO-2 in Modulating JAM-A and γ-Actin Junctional Recruitment, Apical Membrane and Tight Junction Tension, and Cell Response to Substrate Stiffness and Topography

  2024cites this paper
• BP-M345 as a Basis for the Discovery of New Diarylpentanoids with Promising Antimitotic Activity

  2024cites this paper
• Structure-based design and synthesis of BML284 derivatives: A novel class of colchicine-site noncovalent tubulin degradation agents.

  2024cites this paper
• Nanoparticle-loaded microbubbles for treatment of lung cancer.

  2024cites this paper
• Discovery of Novel Diaryl-Substituted Fused Heterocycles Targeting Katanin and Tubulin with Potent Antitumor and Antimultidrug Resistance Efficacy.

  2024cites this paper
• Novel Antimitotic Agent SP-1-39 Inhibits Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• Unveiling the anti-cancer potentiality of phthalimide-based Analogues targeting tubulin polymerization in MCF-7 cancerous Cells: Rational design, chemical Synthesis, and Biological-coupled Computational investigation.

  2024cites this paper
• Fabrication of carbon dots modified electrode for electrochemical sensing of paclitaxel as an important anticancer drug

  2024cites this paper
• Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells

  2024cites this paper
• Dual-targeting inhibitors involving tubulin for the treatment of cancer.

  2024cites this paper
• Supramolecular X-ray and Quantum Chemical Analysis of 4-(2-amino-2-oxoethyl) phenyl 4-methylbenzenesulfonate: A Tosyl Ester Derivative

  2024cites this paper
• Design and evaluation of novel N-substituent diphenylamine derivatives as tubulin colchicine binding site inhibitors.

  2024cites this paper
• A potent Bioorganic azapodophyllotoxin derivative Suppresses tumor Progression in Triple negative breast Cancer: An Insight into its Inhibitory effect on tubulin polymerization and Disruptive effect on microtubule assembly.

  2024cites this paper
• Suppression of microtubule acetylation mediates the anti-leukemic effect of CDK9 inhibition

  2024cites this paper
• Effects of Epothilone D on Social Defeat Stress-induced Changes in Microtubule-related and Endoplasmic Reticulum Stress Protein Expression

  2024cites this paper
• 3-epicaryoptin induces G2/M phase cell cycle arrest and apoptosis in human breast cancer cells by disrupting the microtubule network, an in vitro and in silico investigation

  2024cites this paper
• Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site.

  2024cites this paper
• Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

  2023cites this paper
• Destabilization of microrchidia family CW‐type zinc finger 2 via the cyclin‐dependent kinase 1‐chaperone‐mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule‐targeting agents

  2023cites this paper
• Selection of Optimal Cell Lines for High-Content Phenotypic Screening

  2023cites this paper
• (Bio)electroanalysis of microtubule-targeting agents used in cancer chemotherapy

  2023cites this paper
• Design, synthesis, docking studies and biological screening of 2-pyrimidinyl-2, 3-dihydro-1H-naphtho [1, 2-e][1, 3] oxazines as potent tubulin polymerization inhibitors

  2023cites this paper
• A novel pyrrolidine-2,5-dione derivative induced G2/M phase arrest and apoptosis of hepatocellular carcinoma HepG2 cells through inhibiting tubulin polymerization

  2023cites this paper
• Recent Progress on Microtubule Degradation Agents.

  2023cites this paper
• Indole derivatives targeting colchicine binding site as potential anticancer agents

  2023cites this paper
• Laxiflorin B covalently binds the tubulin colchicine-binding site to inhibit triple negative breast cancer proliferation and induce apoptosis.

  2023cites this paper
• The Potential for Targeting AVIL and Other Actin-Binding Proteins in Rhabdomyosarcoma

  2023cites this paper
• A review of synthetic strategy, SAR, docking, simulation studies, and mechanism of action of isoxazole derivatives as anticancer agents

  2023cites this paper
• Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition.

  2023cites this paper
• Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy

  2023cites this paper
• Investigation of the Antineoplastic Effects of 2-(4-Chlorophenyl)-13α-Estrone Sulfamate against the HPV16-Positive Human Invasive Cervical Carcinoma Cell Line SiHa

  2023cites this paper
• Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers.

  2023cites this paper
• Silicon switch: Carbon–silicon Bioisosteric replacement as a strategy to modulate the selectivity, physicochemical, and drug‐like properties in anticancer pharmacophores

  2023influential citation
• Simple monocyclic pyrimidine analogs as microtubule targeting agents binding to the colchicine site.

  2023cites this paper
• Measurement of Microtubule Stability in Mammalian Cells

  2023cites this paper
• In Silico Exploration of Microtubule Agent Griseofulvin and Its Derivatives Interactions with Different Human β-Tubulin Isotypes

  2023cites this paper
• Selection of optimal cell lines for high-content phenotypic screening

  2023cites this paper
• Phosphate NIMA-Related Kinase 2-Dependent Epigenetic Pathways in Dorsal Root Ganglion Neurons Mediates Paclitaxel-Induced Neuropathic Pain

  2023cites this paper
• Design, synthesis and anti-tumor evaluation of plinabulin derivatives as potential agents targeting β-tubulin.

  2023cites this paper
• Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways

  2023cites this paper
• Development of hydrazide hydrazone-tethered combretastatin-oxindole derivatives as antimitotic agents

  2023cites this paper
• A Ruthenium(II) Polypyridyl Complex Disrupts Actin Cytoskeleton Assembly and Blocks Cytokinesis

  2022cites this paper
• Discovery of Novel N-Heterocyclic-Fused Deoxypodophyllotoxin Analogues as Tubulin Polymerization Inhibitors Targeting the Colchicine-Binding Site for Cancer Treatment.

  2022cites this paper
• Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel

  2022cites this paper
• Synthesis and antitumor activity of litseaone B analogues as tubulin polymerisation inhibitors

  2022cites this paper
• YAP 5-methylcytosine modification increases its mRNA stability and promotes the transcription of exosome secretion-related genes in lung adenocarcinoma

  2022cites this paper
• KC-180-2 Exerts Anti-SCLC Effects via Dual Inhibition of Tubulin Polymerization and Src Signaling

  2022cites this paper
• Sonicated Bordetella bronchiseptica Bacterin Can Protect Dendritic Cells from Differential Cytotoxicity Caused by Doxorubicin and Vincristine and Enhance Their Antigen-Presenting Capability

  2022cites this paper
• Natural products derived from medicinal plants and microbes might act as a game-changer in breast cancer: a comprehensive review of preclinical and clinical studies

  2022cites this paper
• An immunogenic cell injury module for the single-cell multiplexed activity metabolomics platform to identify promising anti-cancer natural products

  2022cites this paper
• Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems

  2022cites this paper
• The past, present, and future of chemotherapy with a focus on individualization of drug dosing.

  2022cites this paper
• Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway.

  2022cites this paper
• A Critical Analysis of Drugs Used in Anticancer Therapy Isolated from the Catharanthus roseus : A Review

  2022cites this paper
• Discovery of 4-methoxy-N-(1-naphthyl)benzenesulfonamide derivatives as small molecule dual-target inhibitors of tubulin and signal transducer and activator of transcription 3 (STAT3) based on ABT-751.

  2022cites this paper
• Structure‐based virtual screening and biological evaluation of novel inhibitors of mycobacterium Z‐ring formation

  2022cites this paper
• A Ruthenium(II) Polypyridyl Complex Disrupts Actin Cytoskeleton Assembly and Blocks Cytokinesis

  2022cites this paper
• Exploiting senescence for the treatment of cancer

  2022cites this paper
• 5-arylalkynyl-2-benzoyl thiophene: a novel microtubule inhibitor exhibits antitumor activity without neurological toxicity.

  2022cites this paper
• Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer.

  2022cites this paper
• A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo.

  2022cites this paper
• Wnt Antagonist as therapeutic targets in Ovarian Cancer.

  2022cites this paper
• Indazole-based microtubule-targeting agents as potential candidates for anticancer drugs discovery.

  2022cites this paper
• Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities.

  2022cites this paper
• Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma

  2022cites this paper
• Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as Microtubule Targeting Agents

  2022cites this paper
• Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine

  2022cites this paper